Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Pfizer

Status: Completed

Conditions: Lung Cancer

Treatments: Drug: Dacomitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04609319

A7471067

Details and patient eligibility

About

This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) treated with dacomitinib as first-line therapy from the date of advanced NSCLC diagnosis to the date of death, lost to follow-up, withdrawal of consent or end of study, whichever occurs first.

Enrollment: 307 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult (aged ≥18 years) with histology-confirmed advanced NSCLC (TNM stage IIIB-IV);
• Presence of any EGFR-activating mutation (exon 19 deletion or exon 21 L858R substitution) or other uncommon EGFR mutations prior to anti-cancer treatment;
• Initiating dacomitinib as first-line treatment after confirmation of EGFR-mutation status (ie, no prior treatment with other EGFR TKI or systemic therapy);

Exclusion criteria

• Enrolled in any interventional clinical study or trial (however, patients enrolled in non-interventional, real world study may still be included).

Trial design

307 participants in 1 patient group

Cohort 1

Treatment:

Drug: Dacomitinib